RxDoctor Payments Data

Fred Petty, MD

Interventional Cardiology · Baton Rouge, LANPI 1841291333

Payments from drug & device makers

$1,529in general payments, 2019–2025

Across 82 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$248
  • Pfizer$244
  • Esperion Therapeutics, Inc.$180
  • Amgen$135
  • Alnylam Pharmaceuticals Inc.$122
  • Irhythm Technologies, Inc.$121
  • plus $480 from 15 others

What the payments were for

  • Food & beverage$1,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,529 in reported general payments places this provider in the 5th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$256,406
Medicare patients
1,003
Services billed
3,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,088$901,404
EntrestoSacubitril/Valsartan113$112,676
XareltoRivaroxaban93$88,525
Repatha SureclickEvolocumab69$48,593
NexletolBempedoic Acid49$22,750
NexlizetBempedoic Acid/Ezetimibe33$16,242
Rosuvastatin Calcium893$10,894
Ezetimibe534$9,176
Atorvastatin Calcium839$8,854
Labetalol Hcl271$5,147
Acebutolol Hcl118$5,060
Metoprolol Succinate507$4,614
Bumetanide254$4,469
LivaloPitavastatin Calcium13$4,179
Losartan Potassium457$3,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$244$901,4041,088 claims
NovartisEntresto$248$112,676113 claims
Johnson & JohnsonXarelto$14$88,52593 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$180$38,99282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →